August 15, 2012

Most Cancer Patients Will Be Treated in Integrated Delivery Networks (IDN) and Cancer Institutions by 2016, Predicts New Report

By 2016, Inside Oncology’s new market intelligence report: Academic Cancer Centers (NCCC): Trends Impacting Key Account Management is predicting that

January 26, 2011

Sorry Rush Limbaugh – Avastin® Reimbursement is “Controlled” by the Compendia NOT the FDA or Medicare!

For those of you who have been following this blog you will recall that I have spent a lot of time discussing cancer drug costs and the lack of

October 14, 2010

Will Medicare Cover Provenge? A Dendreon “Hockey Stick” Event Approaches

While winter is approaching and the hockey season has already begun for sports fans, another kind of hockey related event is approaching

August 24, 2010

Beyond the Tipping Point: Medicare Will Control the Rising Cost of Cancer Drugs

The question is no longer whether or not Medicare will do it but when and how. The initiation of a National Coverage Decision

July 29, 2010

Does Folotyn® work in NSCLC? Allos Therapeutics Reports Phase 2 Results

On Wednesday the 28th Allos announced the results of their randomized phase 2 study comparing Folotyn

July 12, 2010

Buying Opportunities? Dendreon; Antisoma

On July 1st CMS announced that Dendreon’s Provenge® will undergo a National Coverage Determination (NCD).

June 29, 2010

Catch a rising star.

This past ASCO in Chicago was something like the 18th or 19th one that I have attended, and it has grown from a few thousand physicians to